Urelumab

A4DAB284 | Phase-II

Target TNFRSF9/CD137/4-1BB

Isotype / Subclass G4 / None

Company

Bristol-Myers Squibb National Cancer Institute (USA) Ono Pharmaceutical Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University of Chicago Medarex

Clinical Status Phase-II

Format Whole mAb

Synonyms

BMS-663513 BMS663513 BMS 663513 BMS-66513 BMS66513 BMS 66513 ONO-4481 ONO4481 ONO 4481

pH Formulation —

IMGT PubChem (135357295) PubChem (160682619) PubChem (318164830) PubChem (347911279) PubChem (440798814) PubChem (472393043) PubChem (481155343) PubChem (498124040) PubChem (505897364) Thera-SAbDab YAbS

Avg A4D Score

-0.6953

Score Range

-0.72 to -0.67

Structures

Structure ID	Source PDB	Seq. Identity	Avg. A4D Score	pH (Min Agg.)	pH (Max Agg.)	Score CDR	Score non-CDR
A4DAB284_6mhr_A_B	6mhr	100%	-0.6677	6.5	4.0	-0.3053	-0.7149
A4DAB284_6mhr_D_E	6mhr	100%	-0.723	6.5	9.0	-0.3576	-0.7708

Urelumab

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2